Enhertu - Cancer Treatment

Enhertu (fam-trastuzumab deruxtecan-nxki) is a cancer treatment drug that was approved by the US Food and Drug Administration (FDA) in December 2019. It is used to treat certain types of breast cancer that are HER2-positive, meaning that the cancer cells have an overproduction of a protein called HER2. Enhertu is a type of antibody-drug conjugate (ADC), which delivers a powerful chemotherapy drug directly to cancer cells.

How Enhertu Works

Enhertu works by binding to the HER2 protein on cancer cells and delivering a chemotherapy drug to destroy the cancer cells. It is typically administered intravenously, meaning it is delivered into a vein through an IV.

It’s important to note that not all patients will respond to Enhertu, and the drug can have side effects. It’s best to speak with a doctor to determine if Enhertu is the right treatment option for you. They can provide more information on the potential benefits and risks of the drug, and help you make an informed decision about your treatment.

Her2-Low Treatment – Enhertu

HER2-low breast cancer refers to a type of breast cancer where the cancer cells have a low expression of the HER2 protein. HER2 is a protein that helps regulate cell growth and division, and it is often overproduced in certain types of breast cancer, leading to more aggressive and rapid tumor growth.

Treatment for HER2-low breast cancer typically involves a combination of surgery, radiation therapy, and/or systemic therapy (such as chemotherapy, hormone therapy, or targeted therapy). The specific treatment plan will depend on a number of factors, including the stage and location of the cancer, the patient’s overall health, and any other medical conditions they may have.

In general, systemic therapy is the mainstay of treatment for HER2-low breast cancer. Chemotherapy is a common choice for treating HER2-low breast cancer, as it can shrink the size of the tumor and kill cancer cells that have spread to other parts of the body. Hormone therapy may also be used to treat HER2-low breast cancer, particularly in cases where the cancer is hormone receptor-positive. Targeted therapy may also be used in some cases, depending on the specific type of HER2-low breast cancer.

It’s important to work closely with a healthcare team to determine the best treatment plan for your specific situation. They can help you understand the options available and the potential benefits and risks of each.

METASTATIC BREAST CANCER: ENHERTU STOPS THE SPREAD

One in eight women will be diagnosed with breast cancer in their lifetime. Breast cancer is the second leading cause of cancer death for women, behind lung cancer, but after years of clinical trials, the FDA recently approved an exciting new targeted therapy for women with metastatic HER2-low cancer.

Enhertu Breast Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is a treatment drug for certain types of HER2-positive breast cancer. HER2-positive breast cancer is a type of breast cancer where the cancer cells have an overproduction of the HER2 protein, which can lead to more aggressive and rapid tumor growth. Enhertu is a type of antibody-drug conjugate (ADC) that delivers a powerful chemotherapy drug directly to cancer cells.

Enhertu works by binding to the HER2 protein on cancer cells and delivering a chemotherapy drug to destroy the cancer cells. It is typically administered intravenously, meaning it is delivered into a vein through an IV.

In clinical trials, Enhertu has been shown to be effective in treating HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer). It has also been shown to be effective in patients who have received prior treatment with other HER2-targeted therapies, including trastuzumab (Herceptin) and pertuzumab (Perjeta).